Prader-Willi Syndrome (PWS) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Prader-Willi Syndrome (PWS) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Prader-Willi Syndrome (PWS) - Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update, provides an overview of the Prader-Willi Syndrome (PWS) (Genetic Disorders) pipeline landscape.

Prader-Willi Syndrome (PWS) is a rare genetic disorder present at birth that results in a number of physical, mental and behavioral problems. PWS is due to lack of several genes on one of an individual’s two chromosome 15’s.  In the majority of cases, there is a deletion.  In remaining cases, the entire chromosome from the father is missing and there are instead two chromosome 15’s from the mother (uniparental disomy). Symptoms include poor muscle tone, low levels of sex hormones and a constant feeling of hunger.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Prader-Willi Syndrome (PWS) - Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update, provides comprehensive information on the therapeutics under development for Prader-Willi Syndrome (PWS) (Genetic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Prader-Willi Syndrome (PWS) (Genetic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Prader-Willi Syndrome (PWS) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Filing rejected/Withdrawn, Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 1, 2, 6, 6, 6, 3 and 1 respectively. Similarly, the Universities portfolio in Phase II, Preclinical and Discovery stages comprises 1, 1 and 1 molecules, respectively.

Prader-Willi Syndrome (PWS) (Genetic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note:Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

• The pipeline guide provides a snapshot of the global therapeutic landscape of Prader-Willi Syndrome (PWS) (Genetic Disorders).
• The pipeline guide reviews pipeline therapeutics for Prader-Willi Syndrome (PWS) (Genetic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
• The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
• The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
• The pipeline guide reviews key companies involved in Prader-Willi Syndrome (PWS) (Genetic Disorders) therapeutics and enlists all their major and minor projects.
• The pipeline guide evaluates Prader-Willi Syndrome (PWS) (Genetic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
• The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
• The pipeline guide reviews latest news related to pipeline therapeutics for Prader-Willi Syndrome (PWS) (Genetic Disorders)

• Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
• Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
• Find and recognize significant and varied types of therapeutics under development for Prader-Willi Syndrome (PWS) (Genetic Disorders).
• Classify potential new clients or partners in the target demographic.
• Develop tactical initiatives by understanding the focus areas of leading companies.
• Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
• Formulate corrective measures for pipeline projects by understanding Prader-Willi Syndrome (PWS) (Genetic Disorders) pipeline depth and focus of Indication therapeutics.
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
• Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Companies Mentioned
Companies Mentioned

9 Meters Biopharma Inc
Aardvark Therapeutics Inc
Altamira Therapeutics Ltd
Benuvia Therapeutics Inc
Beryl Therapeutics Inc
Biomind Labs Inc
Bioprojet SCR
Carmot Therapeutics Inc
ConSynance Therapeutics Inc
Ferring International Center SA
GLWL Research Inc
Helsinn Group
Inversago Pharma Inc
Lipidio Pharmaceuticals Inc
Lumos Pharma Inc
Neuracle Science Co Ltd
Neuren Pharmaceuticals Ltd
Notitia Biotechnologies Co
OptiNose Inc
OT4B
Saniona AB
Soleno Therapeutics Inc
Taysha Gene Therapies Inc
Tonix Pharmaceuticals Holding Corp